Gilead Sciences Gestion

Gestion contrôle des critères 3/4

Le PDG Gilead Sciences est Dan O'Day, nommé en Mar2019, a un mandat de 5.67 ans. La rémunération annuelle totale est $ 22.61M, composée du salaire de 7.7% et des bonus 92.3%, y compris les actions et options de la société. détient directement 0.04% des actions de la société, d'une valeur de € 42.70M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 6.5 ans.

Informations clés

Dan O'Day

Directeur général

US$22.6m

Rémunération totale

Pourcentage du salaire du PDG	7.7%
Durée du mandat du directeur général	5.7yrs
Propriété du PDG	0.04%
Durée moyenne d'occupation des postes de direction	4.8yrs
Durée moyenne du mandat des membres du conseil d'administration	6.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Dan O'Day a-t-elle évolué par rapport aux bénéfices de Gilead Sciences?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$126m
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$485m
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Rémunération vs marché: La rémunération totale de Dan ($USD 22.61M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 4.74M ).

Rémunération et revenus: La rémunération de Dan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Dan O'Day (60 yo)

5.7yrs

Titularisation

US$22,607,690

Compensation

Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Daniel P. O'Day	Chairman & CEO	5.7yrs	US$22.61m	0.040% € 42.7m
Andrew Dickinson	Chief Financial Officer	5yrs	US$8.11m	0.011% € 12.0m
Deborah Telman	Executive VP of Corporate Affairs	2.3yrs	US$5.27m	0.0017% € 1.8m
Johanna Mercier	Chief Commercial Officer	5.3yrs	US$8.59m	0.0059% € 6.3m
Merdad Parsey	Chief Medical Officer	5yrs	US$8.39m	0.0080% € 8.6m
Sandra Patterson	Senior VP	1.7yrs	pas de données	0.0029% € 3.2m
Jacquie Ross	Vice President of Investor Relations	3.8yrs	pas de données	pas de données
Jyoti Mehra	Executive Vice President of Human Resources	5.3yrs	pas de données	pas de données
Linda Higgins	Senior Vice President of Research	4.8yrs	pas de données	pas de données
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	pas de données	pas de données
Flavius Martin	Executive Vice President of Research	3.6yrs	pas de données	pas de données
William Grossman	Senior Vice President & Therapeutic Area Head of Gilead Oncology	3.3yrs	pas de données	pas de données

4.8yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe de direction de GIS est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Daniel P. O'Day	Chairman & CEO	5.7yrs	US$22.61m	0.040% € 42.7m
Anthony Welters	Lead Independent Director	4.1yrs	US$444.92k	0.00082% € 879.7k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	pas de données
Jacqueline Barton	Independent Director	6.8yrs	US$429.92k	0.0020% € 2.1m
Eugene Schiff	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Robert Schooley	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Harish Manwani	Independent Director	6.5yrs	US$414.92k	0.0010% € 1.1m
John Mellors	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Francis Chisari	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Paul Klotman	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Kelly Kramer	Independent Director	8.3yrs	US$434.92k	0.00011% € 118.0k
Joel Huff	Chairperson of Scientific Advisory Board	no data	pas de données	pas de données

6.5yrs

Durée moyenne de l'emploi

71yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de GIS sont considérés comme expérimentés (ancienneté moyenne 6.5 ans).

Gilead Sciences Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Recent updates

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Third quarter dividend of US$0.77 announced

Third quarter 2024 earnings released: EPS: US$1.01 (vs US$1.75 in 3Q 2023)

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Upcoming dividend of US$0.77 per share

Second quarter dividend of US$0.77 announced

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Second quarter 2024 earnings released: EPS: US$1.29 (vs US$0.84 in 2Q 2023)

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings released: US$3.34 loss per share (vs US$0.81 profit in 1Q 2023)

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Fourth quarter dividend of US$0.77 announced

New minor risk - Financial position

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen